Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium Isoglycyrrhizinate for Prevention of Chemotherapy-Related Liver Injury
NCT01802996Phase 4Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2013
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Magnesium isoglycyrrhizinate in drug induced liver injury (DILI), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
Magnesium isoglycyrrhizinate
03
Conditions
drug induced liver injury (DILI)
Beyond the preview
Go deeper on NCT01802996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01802996.